LONDON–(BUSINESS WIRE)– #ArtificialEyeMarketGrowth–The global artificial eye market is poised to grow by USD 24.6 million during 2019-2023
Author: Business Wire
Asia Pacific Retinal Imaging Devices Market Drivers & Restraints During the Forecast Period, 2019-2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Asia Pacific Retinal Imaging Devices Market (2019-2025)” report has been added to ResearchAndMarkets.com’s offering. The Asia Pacific Retinal Imaging Devices Market is expected to witness market growth of 7.1% CAGR during …
IVERIC bio to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 27, 2020
NEW YORK–(BUSINESS WIRE)–IVERIC bio today announced that it will report its fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020.
Resumen: RIBOMIC anuncia la primera inyección en el ensayo clínico de fase 2 de RMB-007 (estudio TOFU) en sujetos que sufren degeneración macular húmeda asociada con la edad
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., empresa farmacéutica de etapa clínica especializada en terapias con aptámeros y que cotiza en el mercado de Empresas Madres de la Bolsa de Tokio (Número de código: 4591), ha anunciado hoy que se le ha administrado…
RIBOMIC annonce la première injection dans l’essai clinique de phase 2 portant sur le RBM-007 (Étude TOFU) chez des sujets atteints de dégénérescence maculaire liée à l’âge, dans sa forme humide
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., une société pharmaceutique de stade clinique, spécialisée dans les produits thérapeutiques à base d’aptamères, et cotée au Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui qu’un …
RIBOMIC kündigt erste Injektion in der klinischen Phase-2-Studie von RBM-007 (TOFU-Studie) bei Patienten mit feuchter altersbedingter Makula-Degeneration an
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc. ist ein auf Aptamer-Therapeutika spezialisiertes Pharmaunternehmen im klinischen Segment und wird am Mothers Market der Tokioter Börse gehandelt (Codenummer: 4591). Das Unternehmen gab heute bekannt, dass der erste…
Samenvatting: RIBOMIC kondigt eerste injectie aan in de fase 2 klinische studie van RBM-007 (TOFU-studie) bij proefpersonen met wet Age-related Macular Degeneration
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., een farmaceutisch bedrijf in de klinische fase dat gespecialiseerd is in aptameertherapieën en verhandeld wordt op de Mothers markt van de Tokyo Stock Exchange (Codenummer: 4591), kondigde vandaag aan dat de eerst…
RIBOMIC annuncia la somministrazione della prima iniezione nella sperimentazione clinica di Fase 2 su RMB-007 (Studio TOFU) in soggetti affetti da degenerazione maculare senile in forma essudativa
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., una società farmaceutica operante nella fase clinica specializzata in terapie a base di aptameri e quotata sul mercato Mothers della Borsa di Tokyo (codice: 4591), ha annunciato in data odierna la somministrazione…
Global Glass Lens Market 2018-2022 | Availability of Products Through Online Distribution Channels to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)– #GlassLensMarket–The global glass lens market is expected to post a CAGR of around 4% during 2018-2022.
RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
TOKYO–(BUSINESS WIRE)–RIBOMIC Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet Age-Related Macular Degeneration
Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma
SAN DIEGO–(BUSINESS WIRE)–Myopia Management Focus of Pipeline Expansion for Leo Lens Pharma
National Vision Donates More Than 8,100 Pairs of Eyeglasses to Kids in Need
DULUTH, Ga.–(BUSINESS WIRE)–National Vision Holdings, Inc. (NASDAQ: EYE), one of the nation’s largest optical retailers providing quality, affordable eye care and eyewear, today announced that it donated more than 8,100 pairs of free prescription eye…
Fort du succès de la première édition, les HealthTech Innovation Days (HTID®) se tiendront les 22 et 23 juin 2020 à Paris
PARIS–(BUSINESS WIRE)– #biotech–SAVE THE DATE – Fort du succès de la première édition, les HealthTech Innovation Days (HTID®) se tiendront les 22 et 23 juin 2020 à Paris.
Driven by Its Successful Debut, the Second Annual International HealthTech Innovation Days Will Take Place in Paris on June 22nd & 23rd
PARIS–(BUSINESS WIRE)– #biotech–Launched in 2019 by France Biotech and driven by its successful debut, the second annual HealthTech Innovation Days (HTID®) will be held in Paris on June 22nd and June 23rd, 2020. The pre-eminent industry event brings…
FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (s…
Synedgen to Present Data on Therapeutic for Ocular Mustard Gas Injury at NIH-Organized Medical Countermeasures Meeting
CLAREMONT, Calif.–(BUSINESS WIRE)–Synedgen to Present Data on Therapeutic for Ocular Mustard Gas Injury at NIH-Organized Medical Countermeasures Meeting
Be My Eyes Raises $2.8M in Funding for Platform to Support Blind and Visually Impaired Worldwide
SAN FRANCISCO–(BUSINESS WIRE)–Be My Eyes, the mobile app that allows anyone to assist visually impaired people through live video calls, has raised $2.8 million in Series A funding. The investment allows the company to further develop its unique “pur…
Lineage Cell Therapeutics to Present New Data From OpRegen® and Vision Restoration Programs at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2020)
CARLSBAD, Calif.–(BUSINESS WIRE)—- $LCTX #AMD–Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, announced today that updated results from …
Bruker Reports Preliminary Fourth Quarter and Fiscal Year 2019 Operating Results
BILLERICA, Mass.–(BUSINESS WIRE)–Bruker Reports Preliminary Fourth Quarter and Fiscal Year 2019 Operating Results
Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch
GENEVA–(BUSINESS WIRE)–Alcon to Launch Pataday, the Eye Allergy Drop with the #1 Doctor-Prescribed Active Ingredient, following FDA Approval of OTC Switch